More than 6 billion people have returned to the market in five years and attacked innovative drugs!

Recently, Renfu Pharmaceutical, the leading anesthesia and sedation pharmaceutical company, once again sold huge assets to arouse industry attention.

The proportion of pharmaceutical manufacturing rose to 50%, and R&D investment reached 1 billion

Renfu Medicine is a comprehensive pharmaceutical industry group.

Figure 1: Changes in the revenue share of Renfu Medicine's various business segments in recent years

Source: Company Annual Report

According to annual report data, pharmaceutical manufacturing, pharmaceutical wholesale and related businesses have always been the two major operating sectors of Human Welfare Pharmaceuticals, but their gross profit margins are far from each other

Figure 2: Changes in R&D investment in Human Welfare Pharmaceuticals in recent years

Source: Company Annual Report

In order to enrich its product reserves and cultivate long-term competitiveness, Renfu Medicine insists on independent R&D and innovation.

Renfu Medicine has also increased its shareholding ratio in Yichang Renfu, a key subsidiary.

fruitful! 2 Class 1 new drugs and 4 first imitations have successfully broken through

Table 1: The status of Renfu Pharmaceutical's products approved for marketing since 2017

Source: Meinenet MED2.

Continuous R&D investment has brought fruitful results for the company

Renfu Pharmaceutical’s remazolam besylate for injection was reported for production in 2018 and was subsequently included in the priority review.

Midazolam oral solution was reported for production in 2019, and it was included in the priority review and approved in 2021.

In the field of neurological drugs, the company has also been approved for bupropion hydrochloride sustained-release tablets and levobupivacaine hydrochloride injection, and Renfu Medicine has both won the first review

In addition, the company has also received approval for new products in the fields of digestive system and metabolic drugs, cardiovascular system drugs, genitourinary system and sex hormone drugs, and dermatological drugs

Table 2: New drugs declared by Renfu Medicine since 2017 (excluding new indications)

Source: Meinenet MED2.

Renfu Medicine's new drugs under development are also very eye-catching.

In terms of improved new drugs, paracetamol hydrocodone sustained-release tablets, sufentanil transdermal patches, and dexmedetomidine transdermal patches are all suitable for analgesia, and sufentanil transdermal patches are currently undergoing phase I Clinical

Table 3: Generic drugs that Renfu Medicine has reported for production and are under review since 2017

Source: Meinenet MED2.

In terms of generic drugs, Renfu Medicine currently has 3 products under review that are expected to impact the domestic first imitation

In 2019, Renfu Medicine also comprehensively sorted out the product line, and concentrated resources on the development of anesthetics, other nervous system drugs, gender health drugs, Uyghur national drugs, skin external drugs, respiratory system drugs and other core areas.
It is expected that the company will be in the above-mentioned There will be more and more new products in the field
.

Renfu Pharmaceutical "sells a new future", these shares will be sold in 2022

"Focusing on the core" has been the most important task of Renfu Medicine in recent years.
The company firmly withdraws from subdivisions where the competitive advantage is not obvious or the synergy effect is weak, and concentrates resources to build a core product line to form a pharmaceutical industry and a pharmaceutical business.
Supplementary development pattern
.

Table 4: Some large-scale asset sales of Renfu Medicine since 2017

Source: company annual report, semi-annual report, announcement

According to the company's annual report, Renfu Medicine has successively sold business-related assets such as medical services and gender health since 2017, and the cumulative investment income, assets and equity transfer funds totaled more than 6 billion yuan
.
Judging from the company's new product output in the pharmaceutical manufacturing sector in recent years, the withdrawal of funds will play an extremely important role in the company's future development
.
It is reported that Renfu Medicine will continue to promote the equity transfer of Zhengzhou Renfu Bosai Biotechnology, Wuhan Haoyijia Technology and other companies.
It is expected that the above-mentioned projects are expected to land after 2022
.

In the past few years, under the wave of aging, many pharmaceutical companies have begun to "make additions" and actively deploy the big health sector.
In the past two years, medical aesthetics has become a new trend, and listed pharmaceutical companies such as East China Pharmaceutical and Sihuan Pharmaceutical have increased their product introduction.
However, Renfu Medicine "does subtraction" at this time
.

Some people in the industry believe that the sale of assets by pharmaceutical companies is shifting from diversification to the main business.
The divestiture of weak businesses is conducive to focusing on strong businesses.
It can not only meet the needs of the company's strategic transformation in the current operating environment, but also help pharmaceutical companies to further their efforts.
Invigorate assets, optimize resource allocation, and control operating risks
.
Especially with the continuous advancement of the domestic medical reform, leading pharmaceutical companies that "do specialized, refined, and stronger" have more market voices
.

The main force of Renfu Medicine is in the "fine hemp" market, which has strong professionalism and high industry barriers.
Compared with the price cuts brought about by mass procurement, fine hemp medicines are controlled by the state and have better profitability.
Strong stability
.
In recent years, domestic pharmaceutical companies have made remarkable achievements in innovation.
As the leading echelon, Renfu Medicine has also successively won two chemical medicines of category 1 new drugs.
The company's first Chinese patent medicines of category 1 new drugs will soon be available, which is expected to further consolidate the leading position.
After "slimming", Renfu Medicine may usher in a more glorious era
.

Source: Mi Nei.
com database, public company announcements, etc.

Note: The statistics are as of November 25.
If there are any omissions, please correct me!